分子生物学的研究

病態生理学研究の紹介
1.　病態生理とは 2.　統合失調症の病態生理 3.　気分障害・不安障害の病態生理 4.　てんかんの病態生理 5.　パ－キンソン病の病態生理 6.　ADHD・自閉症の病態生理

1.　中枢神経系疾患の病態生理とは
疾病が発症するためには、明らかの

2020
◎Okada, M.; Kawano, Y.; Fukuyama, K.; Motomura, E.; Shiroyama, T. CandidateStrategies for Development of a Rapid-Acting Antidepressant Class That DoesNot Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions. Int J Mol Sci 2020, 21. 10.3390/ijms21217951 ◎Okada, M.; Fukuyama, K.; Shiroyama, T.; Murata, M. A Working HypothesisRegarding Identical Pathomechanisms between Clinical Efficacy and AdverseReaction of Clozapine via the Activation of Connexin43. Int J Mol Sci 2020, 21. 10.3390/ijms21197019 ◎Okada, M.; Hasegawa, T.; Kato, R.; Shiroyama, T. Analysing regionalunemployment rates, GDP per capita and financial support for regional suicideprevention programme on suicide mortality in Japan using governmentalstatistical data. BMJ Open 2020, 10, e037537. 10.1136/bmjopen-2020-037537 ◎Fujii, S.; Motomura, E.; Inui, K.; Watanabe, T.; Hakumoto, Y.; Higuchi, K.;Kawano, Y.; Morimoto, M.; Nakatani, K.; Okada, M. Weaker prepulse exertsstronger suppression of a change-detecting neural circuit. Neurosci Res 2020, 10.1016/j.neures.2020.07.007. 10.1016/j.neures.2020.07.007 ◎Okada, M.; Fukuyama, K. Interaction between Mesocortical and MesothalamicCatecholaminergic Transmissions Associated with NMDA Receptor in the LocusCoeruleus. Biomolecules 2020, 10. 10.3390/biom10070990 ◎Nishijima, H.; Mori, F.; Arai, A.; Zhu, G.; Wakabayashi, K.; Okada, M.; Ueno, S.;Ichinohe, N.; Suzuki, C.; Kon, T., et al. GABA storage and release in the medialglobus pallidus in L-DOPA-induced dyskinesia priming. Neurobiol Dis 2020, 143,104979. 10.1016/j.nbd.2020.104979 ◎Okada, M.; Tominaga, N.; Honda, G.; Nishioka, J.; Akita, N.; Hayashi, T.;Suzuki, K.; Moriuchi, H. A case of thrombomodulin mutation causing defectivethrombin binding with absence of protein C and TAFI activation. Blood Adv2020, 4, 2631-2639. 10.1182/bloodadvances.2019001155 ◎Fukuyama, K.; Ueda, Y.; Okada, M. Effects of Carbamazepine, Lacosamide andZonisamide on Gliotransmitter Release Associated with Activated AstroglialHemichannels. Pharmaceuticals (Basel) 2020, 13. 10.3390/ph13060117 ◎Fukuyama, K.; Fukuzawa, M.; Okada, M. Upregulated and HyperactivatedThalamic Connexin 43 Plays Important Roles in Pathomechanisms of CognitiveImpairment and Seizure of Autosomal Dominant Sleep-Related HypermotorEpilepsy with S284L-Mutant alpha4 Subunit of Nicotinic ACh Receptor.Pharmaceuticals (Basel) 2020, 13. 10.3390/ph13050099 ◎Fukuyama, K.; Fukuzawa, M.; Okubo, R.; Okada, M. Upregulated Connexin 43Induced by Loss-of-Functional S284L-Mutant alpha4 Subunit of Nicotinic AChReceptor Contributes to Pathomechanisms of Autosomal Dominant Sleep-RelatedHypermotor Epilepsy. Pharmaceuticals (Basel) 2020, 13. 10.3390/ph13040058 ◎Fukuyama, K.; Fukuzawa, M.; Shiroyama, T.; Okada, M. Pathomechanism ofnocturnal paroxysmal dystonia in autosomal dominant sleep-related hypermotorepilepsy with S284L-mutant alpha4 subunit of nicotinic ACh receptor. BiomedPharmacother 2020, 126, 110070. 10.1016/j.biopha.2020.110070 ◎Fukuyama, K.; Okubo, R.; Murata, M.; Shiroyama, T.; Okada, M. Activation ofAstroglial Connexin is Involved in Concentration-Dependent Double-EdgedSword Clinical Action of Clozapine. Cells 2020, 9. 10.3390/cells9020414 ◎Fukuyama, K.; Fukuzawa, M.; Shiroyama, T.; Okada, M. Pathogenesis andpathophysiology of autosomal dominant sleep-related hypermotor epilepsy withS284L-mutant alpha4 subunit of nicotinic ACh receptor

2020

◎Okada, M.; Kawano, Y.; Fukuyama, K.; Motomura, E.; Shiroyama, T. CandidateStrategies for Development of a Rapid-Acting Antidepressant Class That DoesNot Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions. Int J Mol Sci 2020, 21. 10.3390/ijms21217951

◎Okada, M.; Fukuyama, K.; Shiroyama, T.; Murata, M. A Working HypothesisRegarding Identical Pathomechanisms between Clinical Efficacy and AdverseReaction of Clozapine via the Activation of Connexin43. Int J Mol Sci 2020, 21. 10.3390/ijms21197019

◎Okada, M.; Hasegawa, T.; Kato, R.; Shiroyama, T. Analysing regionalunemployment rates, GDP per capita and financial support for regional suicideprevention programme on suicide mortality in Japan using governmentalstatistical data. BMJ Open 2020, 10, e037537. 10.1136/bmjopen-2020-037537

◎Fujii, S.; Motomura, E.; Inui, K.; Watanabe, T.; Hakumoto, Y.; Higuchi, K.;Kawano, Y.; Morimoto, M.; Nakatani, K.; Okada, M. Weaker prepulse exertsstronger suppression of a change-detecting neural circuit. Neurosci Res 2020, 10.1016/j.neures.2020.07.007. 10.1016/j.neures.2020.07.007

◎Okada, M.; Fukuyama, K. Interaction between Mesocortical and MesothalamicCatecholaminergic Transmissions Associated with NMDA Receptor in the LocusCoeruleus. Biomolecules 2020, 10. 10.3390/biom10070990

◎Nishijima, H.; Mori, F.; Arai, A.; Zhu, G.; Wakabayashi, K.; Okada, M.; Ueno, S.;Ichinohe, N.; Suzuki, C.; Kon, T., et al. GABA storage and release in the medialglobus pallidus in L-DOPA-induced dyskinesia priming. Neurobiol Dis 2020, 143,104979. 10.1016/j.nbd.2020.104979

◎Okada, M.; Tominaga, N.; Honda, G.; Nishioka, J.; Akita, N.; Hayashi, T.;Suzuki, K.; Moriuchi, H. A case of thrombomodulin mutation causing defectivethrombin binding with absence of protein C and TAFI activation. Blood Adv2020, 4, 2631-2639. 10.1182/bloodadvances.2019001155

◎Fukuyama, K.; Ueda, Y.; Okada, M. Effects of Carbamazepine, Lacosamide andZonisamide on Gliotransmitter Release Associated with Activated AstroglialHemichannels. Pharmaceuticals (Basel) 2020, 13. 10.3390/ph13060117

◎Fukuyama, K.; Fukuzawa, M.; Okada, M. Upregulated and HyperactivatedThalamic Connexin 43 Plays Important Roles in Pathomechanisms of CognitiveImpairment and Seizure of Autosomal Dominant Sleep-Related HypermotorEpilepsy with S284L-Mutant alpha4 Subunit of Nicotinic ACh Receptor.Pharmaceuticals (Basel) 2020, 13. 10.3390/ph13050099

◎Fukuyama, K.; Fukuzawa, M.; Okubo, R.; Okada, M. Upregulated Connexin 43Induced by Loss-of-Functional S284L-Mutant alpha4 Subunit of Nicotinic AChReceptor Contributes to Pathomechanisms of Autosomal Dominant Sleep-RelatedHypermotor Epilepsy. Pharmaceuticals (Basel) 2020, 13. 10.3390/ph13040058

◎Fukuyama, K.; Fukuzawa, M.; Shiroyama, T.; Okada, M. Pathomechanism ofnocturnal paroxysmal dystonia in autosomal dominant sleep-related hypermotorepilepsy with S284L-mutant alpha4 subunit of nicotinic ACh receptor. BiomedPharmacother 2020, 126, 110070. 10.1016/j.biopha.2020.110070

◎Fukuyama, K.; Okubo, R.; Murata, M.; Shiroyama, T.; Okada, M. Activation ofAstroglial Connexin is Involved in Concentration-Dependent Double-EdgedSword Clinical Action of Clozapine. Cells 2020, 9. 10.3390/cells9020414

◎Fukuyama, K.; Fukuzawa, M.; Shiroyama, T.; Okada, M. Pathogenesis andpathophysiology of autosomal dominant sleep-related hypermotor epilepsy withS284L-mutant alpha4 subunit of nicotinic ACh receptor

2019
◎Kato, R.; Okada, M. Can Financial Support Reduce Suicide Mortality Rates?Int J Environ Res Public Health 2019, 16. 10.3390/ijerph16234797 ◎Okada, M.; Fukuyama, K.; Nakano, T.; Ueda, Y. Pharmacological Discriminationof Effects of MK801 on Thalamocortical, Mesothalamic, and MesocorticalTransmissions. Biomolecules 2019, 9. 10.3390/biom9110746 ◎Nakano, T.; Hasegawa, T.; Suzuki, D.; Motomura, E.; Okada, M. AmantadineImproves Delayed Neuropsychiatric Sequelae of Carbon Monoxide Poisoning: ACase Report. Brain Sci 2019, 9. 10.3390/brainsci9110292 ◎Okada, M.; Fukuyama, K.; Okubo, R.; Shiroyama, T.; Ueda, Y. Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1Aand 5-HT7 Receptors in Dorsal Raphe Nucleus. Pharmaceuticals (Basel) 2019, 12. 10.3390/ph12040149 ◎Motomura, E.; Inui, K.; Kawano, Y.; Nishihara, M.; Okada, M. Effects of Sound-Pressure Change on the 40 Hz Auditory Steady-State Response and Change-Related Cerebral Response. Brain Sci 2019, 9. 10.3390/brainsci9080203 ◎Okada, M.; Fukuyama, K.; Shiroyama, T.; Ueda, Y. Carbamazepine AttenuatesAstroglial L-Glutamate Release Induced by Pro-Inflammatory Cytokines viaChronically Activation of Adenosine A2A Receptor. Int J Mol Sci 2019, 20. 10.3390/ijms20153727 ◎Okada, M.; Fukuyama, K.; Ueda, Y. Lurasidone inhibits NMDA receptorantagonist-induced functional abnormality of thalamocortical glutamatergictransmission via 5-HT7 receptor blockade. Br J Pharmacol 2019, 176, 4002-4018. 10.1111/bph.14804 ◎Fukuyama, K.; Kato, R.; Murata, M.; Shiroyama, T.; Okada, M. ClozapineNormalizes a Glutamatergic Transmission Abnormality Induced by an ImpairedNMDA Receptor in the Thalamocortical Pathway via the Activation of a GroupIII Metabotropic Glutamate Receptor. Biomolecules 2019, 9. 10.3390/biom9060234 ◎Nakano, T.; Hasegawa, T.; Suzuki, D.; Motomura, E.; Okada, M. AmantadineCombines Astroglial System Xc(-) Activation with Glutamate/NMDA ReceptorInhibition. Biomolecules 2019, 9. 10.3390/biom9050191 ◎Okada, M.; Fukuyama, K.; Kawano, Y.; Shiroyama, T.; Suzuki, D.; Ueda, Y.Effects of acute and sub-chronic administrations of guanfacine oncatecholaminergic transmissions in the orbitofrontal cortex. Neuropharmacology2019, 156, 107547. 10.1016/j.neuropharm.2019.02.029 ◎Okada, M.; Fukuyama, K.; Kawano, Y.; Shiroyama, T.; Ueda, Y. Memantineprotects thalamocortical hyper-glutamatergic transmission induced by NMDAreceptor antagonism via activation of system xc<sup/>. Pharmacol Res Perspect2019, 7, e00457. 10.1002/prp2.457 ◎Tanahashi, S.; Yamamura, S.; Nakagawa, M.; Motomura, E.; Okada, M.Corrigendum to "Dopamine D2 and serotonin 5-HT1A receptors mediate theactions of aripiprazole in mesocortical and mesoaccumbens transmission"[Neuropharmacology 62 (2012) 765-774]. Neuropharmacology 2019, 148, 406. 10.1016/j.neuropharm.2018.11.001

2019

◎Kato, R.; Okada, M. Can Financial Support Reduce Suicide Mortality Rates?Int J Environ Res Public Health 2019, 16. 10.3390/ijerph16234797

◎Okada, M.; Fukuyama, K.; Nakano, T.; Ueda, Y. Pharmacological Discriminationof Effects of MK801 on Thalamocortical, Mesothalamic, and MesocorticalTransmissions. Biomolecules 2019, 9. 10.3390/biom9110746

◎Nakano, T.; Hasegawa, T.; Suzuki, D.; Motomura, E.; Okada, M. AmantadineImproves Delayed Neuropsychiatric Sequelae of Carbon Monoxide Poisoning: ACase Report. Brain Sci 2019, 9. 10.3390/brainsci9110292

◎Okada, M.; Fukuyama, K.; Okubo, R.; Shiroyama, T.; Ueda, Y. Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1Aand 5-HT7 Receptors in Dorsal Raphe Nucleus. Pharmaceuticals (Basel) 2019, 12. 10.3390/ph12040149

◎Motomura, E.; Inui, K.; Kawano, Y.; Nishihara, M.; Okada, M. Effects of Sound-Pressure Change on the 40 Hz Auditory Steady-State Response and Change-Related Cerebral Response. Brain Sci 2019, 9. 10.3390/brainsci9080203

◎Okada, M.; Fukuyama, K.; Shiroyama, T.; Ueda, Y. Carbamazepine AttenuatesAstroglial L-Glutamate Release Induced by Pro-Inflammatory Cytokines viaChronically Activation of Adenosine A2A Receptor. Int J Mol Sci 2019, 20. 10.3390/ijms20153727

◎Okada, M.; Fukuyama, K.; Ueda, Y. Lurasidone inhibits NMDA receptorantagonist-induced functional abnormality of thalamocortical glutamatergictransmission via 5-HT7 receptor blockade. Br J Pharmacol 2019, 176, 4002-4018. 10.1111/bph.14804

◎Fukuyama, K.; Kato, R.; Murata, M.; Shiroyama, T.; Okada, M. ClozapineNormalizes a Glutamatergic Transmission Abnormality Induced by an ImpairedNMDA Receptor in the Thalamocortical Pathway via the Activation of a GroupIII Metabotropic Glutamate Receptor. Biomolecules 2019, 9. 10.3390/biom9060234

◎Nakano, T.; Hasegawa, T.; Suzuki, D.; Motomura, E.; Okada, M. AmantadineCombines Astroglial System Xc(-) Activation with Glutamate/NMDA ReceptorInhibition. Biomolecules 2019, 9. 10.3390/biom9050191

◎Okada, M.; Fukuyama, K.; Kawano, Y.; Shiroyama, T.; Suzuki, D.; Ueda, Y.Effects of acute and sub-chronic administrations of guanfacine oncatecholaminergic transmissions in the orbitofrontal cortex. Neuropharmacology2019, 156, 107547. 10.1016/j.neuropharm.2019.02.029

◎Okada, M.; Fukuyama, K.; Kawano, Y.; Shiroyama, T.; Ueda, Y. Memantineprotects thalamocortical hyper-glutamatergic transmission induced by NMDAreceptor antagonism via activation of system xc<sup/>. Pharmacol Res Perspect2019, 7, e00457. 10.1002/prp2.457

◎Tanahashi, S.; Yamamura, S.; Nakagawa, M.; Motomura, E.; Okada, M.Corrigendum to "Dopamine D2 and serotonin 5-HT1A receptors mediate theactions of aripiprazole in mesocortical and mesoaccumbens transmission"[Neuropharmacology 62 (2012) 765-774]. Neuropharmacology 2019, 148, 406. 10.1016/j.neuropharm.2018.11.001